Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian
  • Portuguese

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Colorectal cancer: a bacterium is a key player in chemoresistance
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Colorectal cancer: a bacterium is a key player in chemoresistance
Gastroenterology

Colorectal cancer: a bacterium is a key player in chemoresistance

Cancer
Oncology Gastroenterology

According to a Chinese study, the presence of Fusobacterium nucleatum in tumor cells might significantly reduce the efficacy of one of the standard adjuvant chemotherapies for colorectal cancer.

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • Mail

About this article

Created 23 April 2019
Updated 06 October 2021

 

The focus on gut dysbiosis was introduced into oncology research following the observation in a growing number of studies that the intestinal microbiota may play a role in resistance to or potentiation of some anti-cancer treatments. For example, Fusobacterium nucleatum (Fn)–an anaerobic bacterium present in the oral cavity, where it can cause periodontitis–was recently linked to carcinogenesis and the progression of colorectal cancer (CRC).

Impact on cytotoxicity

Tests carried out on colorectal cancer cell lines showed that Fn significantly upregulated expression of BIRC3, a protein that inhibits (sidenote: Apoptosis Physiological programmed cell death process ) . The latter is one of the presumed mechanisms of action of 5-Fluorouracil (5-Fu), a standard adjuvant chemotherapy for CRC: Fn and 5-Fu would therefore have competing actions in the process of tumor destruction. Additional in vitro and in vivo analyses confirmed that Fn directly reduced thecytotoxicity–therefore the efficacy–of 5-Fu.

Increased risk of relapse

What is the mechanism involved? Stimulation of receptors present on the surface of immune cells (Toll-like receptors 4, or TLR4) by bacteria via membrane wall components. This stimulation activates a signaling pathway, which in turn induces expression of BIRC3 in the cancer cells. These results were confirmed by analyzing biopsies of 94 patients with advanced stage CRC and treated with 5‑Fu: the abundance of Fn was increased in 22.3 % of samples, as was expression of BIRC3 and TLR4. Higher levels of these two indicators were also detected in patients who had relapsed. The researchers consider that Fn and BIRC3 could therefore serve as therapeutic targets to reduce resistance to chemotherapy in advanced-stage CRC.

Other cancers in the line of sight

A previous study demonstrated the potential of treatment with metronidazole to reduce tumor growth in mouse models of CRC: however, further work is needed to confirm that this antibiotic therapy is suitable for blocking chemoresistance to 5-Fu before considering its use in clinical practice. This could also be applicable to other types of cancer since BIRC3 has been associated with chemoresistance to 5-FU in pancreatic cancer and to doxorubicin in breast cancer.

 

Sources

Zhang S, Yang Y, Weng W et al. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. J Exp Clin Cancer Res. 2019 Jan 10;38(1):14

https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-12-86

Tags
Drug interaction Resistance Colorectal cancer Chemotherapy Fusobacterium nucleatum Cancer CRC

en_view en_sources

    Created 23 April 2019
    Updated 06 October 2021

    About this article

    To know more about this topic.

    Main topic

    Cancer

    Medical practice

    Oncology Gastroenterology

    Content type

    News
    Gastroenterology

    The blue poop challenge: a reliable method to evaluate gut transit?

    By Pr. Gianluca Ianiro Gastroenterology Department, Fondazione Policlinico Universitario Agostino Gemelli- ...

    Find out more

    New perspectives in autism: the role of microbiota in social communication

    Overview By Dr. Vincent Trebossen Child and Adolescent P...

    Find out more

    Gut microbiota #15

    By Pr. Markku Voutilainen Turku University Faculty of Medicine; Turku University Hospital, Department of Ga...

    Find out more

    Microbiome topics at gastro 2021

    Congress Review By Pr. Eamonn M M Quigley Lynda K and David M Underwood Center for Digestive Disorders, Di...

    Find out more

    Commensal clostridiales strains mediate effective anti-cancer immune response against solid tumours

    Commented articles - Adults' section By Pr. Harry Sokol ...

    Find out more

    Microbiota in covid-19 pandemic

    Overview By Pr. Conceição Calhau NOVA Medical School, New University of Lisbon, Portugal By Pr. Pedro Povo...

    Find out more

    Association between fungal dysbiosis and environment

    The fungal portion of the gut microbiota (or mycobiota) has been much less studied than the bacterial porti...

    Find out more

    From diarrhea to chronic diseases: the well-documented consequences of antibiotic-related gut microbiota dysbiosis

    Antibiotic treatment may sometimes take place without any...

    Find out more

    Continue reading

    News
    22.11.2021

    Irritable bowel syndrome: is fecal microbiota transplantation effective in the long term?

    Read the article
    Cancer du pancréas : un diagnostic précoce non invasif grâce au microbiote fécal ?
    16.06.2022

    Pancreatic cancer: non-invasive early diagnosis thanks to the fecal microbiota?

    Read the article
    Photo: Régime méditerranéen « vert » : quels liens entre santé cardiométabolique et microbiote intestinal ?
    10.06.2022

    Green Mediterranean diet: what links between cardiometabolic health and gut microbiota?

    Read the article
    Immune checkpoint inhibitor (ICI) efficacy: the right dose of bacteria
    02.06.2022

    Immune checkpoint inhibitor (ICI) efficacy: the right dose of bacteria

    Read the article
    18.05.2022

    Gut microbiota and vitamin D: a promising team in the fight against osteoporosis?

    Read the article
    Photo: Neonatal sepsis: the microbiota pays a heavy price for antibiotic use
    09.05.2022

    Neonatal sepsis: the microbiota pays a heavy price for antibiotic use

    Read the article
    26.04.2022

    Severe obesity: the vicious circle of biotin metabolism

    Read the article
    22.04.2022

    SCFAs: new intestinal markers of Parkinson’s disease?

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian
    • Portuguese

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    Photo: Postménopause : l'action bénéfique de l'estradiol sur le microbiote vaginal
    22.06.2022

    Postmenopause: the beneficial action of estradiol on the vaginal microbiota

    Read the article
    WMD_Foundation KOL USA 2018
    17.06.2022

    Dr. Yang (USA winner 2018): Gut microbiota & gut brain axis

    Read the article
    WMD_Foundation KOL USA 2017
    17.06.2022

    Dr. Singh (USA winner 2017): Microbiota & polyphenols

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo